STAT+: Pharma is a ‘mixed bag’ when providing drug access to low- and middle-income countries, analysis finds
Many large pharmaceutical companies are taking steps to improve access to their medicines in low- and middle-income countries, but progress has been mixed and more action is needed to ensure wide availability, a new analysis found. Notably, more drugmakers are planning to reach patients before a product launch — access plans now cover 69% of late-stage pipeline candidates compared with 18% in 2018. And across the pipeline, 95% of late-stage experimental drugs developed with a nonprofit partner h...
Read full article →